RT Journal
A1 Cuccia CA
T1 THe radiation attack
JF JAMA
JO JAMA
YR 1969
FD January 13
VO 207
IS 2
SP 347
OP 348
DO 10.1001/jama.1969.03150150059014
UL http://dx.doi.org/10.1001/jama.1969.03150150059014
AB Supervoltage therapy has definitely proven its superiority over orthovoltage therapy in the treatment of carcinoma of the urinary bladder. The advantages of such a modality are so obvious that, in the treatment of deeply infiltrating, high-grade carcinomas of the urinary bladder, radiation therapy, which was originally of dubious usefulness, has become the treatment of choice.In the past, orthovoltage radiotherapy, plagued by its many limitations, such as severe skin reactions, poor patient tolerance, marked radiation cystitis, inability to deliver a cancericidal dose, and unsatisfactory tumor control, was only able to provide a five-year survival frequency not exceeding 5%.Supervoltage therapy (with 1 million to 24 million volts, cesium 137, or cobalt [60Co]), being able to deliver a cancericidal dose to the pelvis or bladder with reduced reactions and a small incidence of complications, has drastically improved such results.In addition to the technical advantages offered by supervoltage equipment, a